Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).
NEW YORK, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 24th Annual Oppenheimer Healthcare Conference in New York City. Seth Lederman, M.D., president and CEO of Tonix, will deliver a corporate overview on Tuesday, December 10, 2013 at 3:55 PM ET.
The presentation will be webcast live and may be accessed in the Events tab of the Investor Relations page of Tonix's website at www.tonixpharma.com. The webcast will be archived for 60 days.
Tonix will also be available for one-on-one meetings at the conference.
"We are developing TNX-102 SL with the goal of offering an important new therapeutic option for fibromyalgia patients, and remain on track to announce results from the BESTFIT trial in the second half of next year," said Seth Lederman, M.D., president and CEO of Tonix. "Of note, and also taking place on December 10, the Food and Drug Administration will hold its Fibromyalgia Public Meeting on Patient-Focused Drug Development in Silver Spring, MD. This meeting is intended to allow the FDA to obtain patients' perspectives on the impact of fibromyalgia on their daily lives, as well as on the available therapies for this syndrome. We believe this event will reaffirm the value of our development program and tell an important part of the Tonix story to investors."
About Tonix Pharmaceuticals Holding Corp.
Tonix is developing innovative prescription medications for challenging disorders of the central nervous system. Tonix seeks to address conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. Tonix is advancing its lead therapeutic candidate TNX-102 SL for the management of fibromyalgia and PTSD. Tonix is currently enrolling patients into the first anticipated pivotal trial of TNX-102 SL in fibromyalgia, the BESTFIT trial (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy). Tonix applies its core technology toward the treatment of people suffering from fibromyalgia and PTSD by targeting their inability to obtain restorative sleep. To learn more, please visit www.tonixpharma.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on TONIX's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. TONIX does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 11, 2013 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
CONTACT: Tonix Pharmaceuticals Holding Corp. Leland Gershell Chief Financial Officer (212) 980-9155 x104 email@example.com Investor Relations: CorProminence Chuck Bennett (516) 222-2285 firstname.lastname@example.org Public Relations: JQA Partners, LLC Jules Abraham (917) 885-7378 email@example.comSource: Tonix Pharmaceuticals Holding, Inc.